5,176 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Quantinno Capital Management LP

Quantinno Capital Management LP purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,176 shares of the company’s stock, valued at approximately $254,000.

A number of other large investors have also recently bought and sold shares of the stock. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in shares of Oruka Therapeutics during the third quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth approximately $67,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $43,000. 56.44% of the stock is currently owned by institutional investors.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the sale, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,116 shares of company stock valued at $6,636,533 in the last three months. Company insiders own 23.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ORKA shares. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a report on Monday, August 3rd. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a report on Thursday, April 30th. UBS Group lifted their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Finally, Barclays increased their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $102.42 on Tuesday. The stock has a market capitalization of $6.78 billion, a P/E ratio of -50.45 and a beta of -0.34. Oruka Therapeutics, Inc. has a 52 week low of $14.34 and a 52 week high of $115.51. The stock has a fifty day moving average of $92.49 and a 200-day moving average of $65.93.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.